Maxalt
Product Images NDC 21695-956

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Maxalt (NDC 21695-956). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Structural Formula (3f30e6a5 F3c0 4c20 B1a2 142575eb0e24 01)

Chemical structure diagram of the active ingredient in MAXALT, showing molecular connections and functional groups including an indole moiety, methylated amine side chain, and carboxylic acid phenyl ring.*

FDA Label Image

Image Of Figure 1 (3f30e6a5 F3c0 4c20 B1a2 142575eb0e24 02)

Kaplan-Meier plot showing the probability over time (up to 2 hours post-dose) of achieving a headache response for Placebo, MAXALT 5 mg, and MAXALT 10 mg treatment groups. The graph displays estimated probability of response on the vertical axis and time in hours on the horizontal axis, illustrating increasing response rates for higher doses compared to placebo.*

FDA Label Image

Image Of Figure 2 (3f30e6a5 F3c0 4c20 B1a2 142575eb0e24 03)

A Kaplan-Meier plot comparing the estimated probability of headache medication or rescue response over 24 hours post-dose for placebo, MAXALT 5 mg, and MAXALT 10 mg. The graph illustrates data from four placebo-controlled outpatient clinical trials, showing increasing response probability over time for both MAXALT doses compared to placebo.*

FDA Label Image

Image Of Figure 3 (3f30e6a5 F3c0 4c20 B1a2 142575eb0e24 04)

Kaplan-Meier plot depicting the probability of obtaining headache response over time after dosing with MAXALT-MLT 5 mg, MAXALT-MLT 10 mg, and placebo. The graph shows response rates increasing up to 2 hours post-dose, with higher response observed for 10 mg compared to 5 mg and placebo.*

FDA Label Image

Image Of Figure 4 (3f30e6a5 F3c0 4c20 B1a2 142575eb0e24 05)

A Kaplan-Meier plot showing the estimated probability of remission on relief over 24 hours post-dose. The plot compares Placebo, MAXALT-MLT 5 mg, and MAXALT-MLT 10 mg treatments, with data from two placebo-controlled outpatient clinical trials. The x-axis represents hours post-dose, and the y-axis shows the probability percentage of remission or relief.*

FDA Label Image

Maxalt 10mg (3f30e6a5 F3c0 4c20 B1a2 142575eb0e24 06)

Maxalt 10 mg tablets label by Rebel Distributors Corp. The label states each tablet contains 14.53 mg Rizatriptan Benzoate, equivalent to 10 mg rizatriptan. The tablets are described as pale pink, capsule-shaped, and compressed, coded with "MAXALT" on one side and "MRK 267" on the other. Pack contains 18 tablets. Distributed by Physician Partner, Thousand Oaks, CA, with storage instructions at controlled room temperature 15°-30°C (59°-86°F). Manufacturer noted as MSD, Ltd., UK.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.